Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2026-01-01 @ 3:31 PM
Study NCT ID:
NCT01068756
Status:
TERMINATED
Last Update Posted:
2016-10-17
First Post:
2010-02-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
Status:
TERMINATED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: